{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T21:37:44Z","timestamp":1788385064766,"version":"build-2803163510"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81903917"],"award-info":[{"award-number":["No. 81903917"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>TongFengTangSan (TFTS) is a commonly used Tibetan prescription for gout treatment. Previously, TFTS (CF) was confirmed to have a significant uric acid-lowering effect. However, the anti-hyperuricemia mechanisms and the main active fractions remain unclear. The current study aimed to investigate the anti-hyperuricemia mechanism using metabolomics and confirm the active CF fraction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The hyperuricemia model was established through intraperitoneal injection containing 100\u00a0mg\/kg potassium oxonate and 150\u00a0mg\/kg hypoxanthine by gavage. We used serum uric acid (sUA), creatinine (CRE), blood urea nitrogen (BUN), xanthine oxidase (XOD) activity, interleukin-6 (IL-6) and interleukin-1\u03b2 (IL-1\u03b2) as indicators to evaluate the efficacy of CF and the four fractions (SX, CF30, CF60, and CF90). The anti-hyperuricemia mechanism of CF was considered through non-targeted metabolomics depending on the UPLC-Q-TOF\u2013MS technology. Principle component analysis (PCA) and orthogonal partial least squares-discriminant analysis (OPLS-DA) helped explore the potential biomarkers in hyperuricemia. Moreover, the differential metabolites and metabolic pathways regulated by CF and four fractions were also assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>CF revealed a significant anti-hyperuricemia effect by down-regulating the level of sUA, sCRE, sIL-1\u03b2, and XOD. SX, CF30, CF60, and CF90 differed in the anti-hyperuricemia effect. Only CF60 significantly lowered the sUA level among the four fractions, and it could be the main efficacy fraction of TFTS. Forty-three differential metabolites were identified in hyperuricemia rats from plasma and kidney. Pathway analysis demonstrated that seven pathways were disrupted among hyperuricemia rats. CF reversed 19 metabolites in hyperuricemia rats and exerted an anti-hyperuricemia effect by regulating purine metabolism. CF60 was the main active fraction of TFTS and exerted a similar effect of CF by regulating purine metabolism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CF and CF60 could exert an anti-hyperuricemia effect by regulating the abnormal purine metabolism because of hyperuricemia while improving intestinal and renal function. CF60 could be the main active fraction of TFTS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13020-023-00716-w","type":"journal-article","created":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T05:03:08Z","timestamp":1676523788000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Exploration of the anti-hyperuricemia effect of TongFengTangSan (TFTS) by UPLC-Q-TOF\/MS-based non-targeted metabonomics"],"prefix":"10.1186","volume":"18","author":[{"given":"Zhichao","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wugang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifang","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,16]]},"reference":[{"issue":"10055","key":"716_CR1","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1016\/S0140-6736(16)00346-9","volume":"388","author":"N Dalbeth","year":"2016","unstructured":"Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016;388(10055):2039\u201352.","journal-title":"Lancet"},{"issue":"6","key":"716_CR2","doi-asserted-by":"publisher","first-page":"700","DOI":"10.2174\/1381612825666190408122557","volume":"25","author":"S Zhang","year":"2019","unstructured":"Zhang S, Wang Y, Cheng J, Huangfu N, Zhao R, Xu Z, Zhang F, Zheng W, Zhang D. Hyperuricemia and cardiovascular disease. Curr Pharm Des. 2019;25(6):700\u20139.","journal-title":"Curr Pharm Des"},{"key":"716_CR3","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3389\/fmed.2018.00160","volume":"5","author":"CL Benn","year":"2018","unstructured":"Benn CL, Dua P, Gurrell R, Loudon P, Pike A, Storer RI, Vangjeli C. Physiology of hyperuricemia and urate-lowering treatments. Front Med. 2018;5:160.","journal-title":"Front Med"},{"issue":"7","key":"716_CR4","first-page":"3167","volume":"12","author":"L Li","year":"2020","unstructured":"Li L, Zhang Y, Zeng C. Update on the epidemiology, genetics, and therapeutic options of hyperuricemia. Am J Transl Res. 2020;12(7):3167\u201381.","journal-title":"Am J Transl Res"},{"issue":"12","key":"716_CR5","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1007\/s10067-017-3851-y","volume":"36","author":"BJ Paul","year":"2017","unstructured":"Paul BJ, Anoopkumar K, Krishnan V. Asymptomatic hyperuricemia: is it time to intervene? Clin Rheumatol. 2017;36(12):2637\u201344.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"716_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/BOR.0000000000000679","volume":"32","author":"K Yip","year":"2020","unstructured":"Yip K, Cohen RE, Pillinger MH. Asymptomatic hyperuricemia: is it really asymptomatic? Curr Opin Rheumatol. 2020;32(1):71\u20139.","journal-title":"Curr Opin Rheumatol"},{"issue":"4","key":"716_CR7","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1080\/14740338.2019.1594771","volume":"18","author":"L Strilchuk","year":"2019","unstructured":"Strilchuk L, Fogacci F, Cicero AF. Safety and tolerability of available urate-lowering drugs: a critical review. Expert Opin Drug Saf. 2019;18(4):261\u201371.","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"716_CR8","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1080\/17425255.2017.1269745","volume":"13","author":"RO Day","year":"2017","unstructured":"Day RO, Kannangara DR, Stocker SL, Carland JE, Williams KM, Graham GG. Allopurinol: insights from studies of dose-response relationships. Expert Opin Drug Metab Toxicol. 2017;13(4):449\u201362.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"716_CR9","volume-title":"Tibetan Medicine Standard","author":"Tibet Health Bureau","year":"1979","unstructured":"Tibet Health Bureau. Tibetan Medicine Standard. Qinghai: Qinghai People\u2019s Publishing Press Xining; 1979."},{"key":"716_CR10","unstructured":"Li D L, Xu C L, Yang S S, Cheng B S, D Z Z. Great Dictionary of Chinese Medicine. Beijing: China Pharmaceutical Science and Technology Press; 1991."},{"key":"716_CR11","first-page":"61","volume":"38","author":"JC Dajie","year":"2018","unstructured":"Dajie JC. Analysis on the clinical effective rate of Tibetan medicine Tongfeng Decoction in the treatment of zhinai (gout). Health Guide. 2018;38:61.","journal-title":"Health Guide"},{"issue":"04","key":"716_CR12","first-page":"1","volume":"23","author":"XW Nanjie","year":"2017","unstructured":"Nanjie XW, Cairang ZM. Clinical observation of Tibetan medicine Tongfeng Decoction in the treatment of zhinai (gout). Chin J Ethnomed Ethnopharm. 2017;23(04):1\u20132.","journal-title":"Chin J Ethnomed Ethnopharm"},{"key":"716_CR13","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jpba.2018.11.038","volume":"165","author":"HF Chen","year":"2019","unstructured":"Chen HF, Zhang C, Yao Y, Li JM, Du WD, Li ML, Wu B, Yang SL, Feng YL, Zhang WG. Study on anti-hyperuricemia effects and active ingredients of traditional Tibetan medicine TongFengTangSan (TFTS) by ultra-high-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry. J Pharm Biomed Anal. 2019;165:213\u201323.","journal-title":"J Pharm Biomed Anal"},{"key":"716_CR14","doi-asserted-by":"publisher","first-page":"114135","DOI":"10.1016\/j.jep.2021.114135","volume":"275","author":"XR Zhang","year":"2021","unstructured":"Zhang XR, Qiao YJ, Zhu HT, Kong QH, Wang D, Yang CR, Zhang YJ. Multiple in vitro biological effects of phenolic compounds from Terminalia chebula var tomentella. J Ethnopharmacol. 2021;275:114135.","journal-title":"J Ethnopharmacol"},{"key":"716_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.prmcm.2022.100163","volume":"5","author":"AK Dhingra","year":"2022","unstructured":"Dhingra AK, Chopra B, Grewal AS, Guarve K. Pharmacological properties of Chebulinic acid and related ellagitannins from nature: an emerging contemporary bioactive entity. Pharmacol Res Modern Chinese Med. 2022;5: 100163.","journal-title":"Pharmacol Res Modern Chinese Med"},{"issue":"19","key":"716_CR16","doi-asserted-by":"publisher","first-page":"5901","DOI":"10.1016\/j.bmcl.2011.07.086","volume":"21","author":"H Ishimoto","year":"2011","unstructured":"Ishimoto H, Shibata M, Myojin Y, Ito H, Sugimoto Y, Tai A, Hatano T. In vivo anti-inflammatory and antioxidant properties of ellagitannin metabolite urolithin A. Bioorg Med Chem Lett. 2011;21(19):5901\u20134.","journal-title":"Bioorg Med Chem Lett"},{"key":"716_CR17","first-page":"1125","volume":"6","author":"AT Pham","year":"2011","unstructured":"Pham AT, Malterud KE, Paulsen BS, Diallo D, Wangensteen H. DPPH Radical scavenging and xanthine oxidase inhibitory activity of Terminalia macroptera Leaves. Nat Prod Commun. 2011;6:1125\u20138.","journal-title":"Nat Prod Commun"},{"key":"716_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108107","volume":"100","author":"Y Wang","year":"2021","unstructured":"Wang Y, Zhu W, Lu D, Zhang C, Wang Y. Tetrahydropalmatine attenuates MSU crystal-induced gouty arthritis by inhibiting ROS-mediated NLRP3 inflammasome activation. Int Immunopharmacol. 2021;100: 108107.","journal-title":"Int Immunopharmacol"},{"key":"716_CR19","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jpba.2014.12.017","volume":"113","author":"R Bujak","year":"2015","unstructured":"Bujak R, Struck-Lewicka W, Markuszewski MJ, Kaliszan R. Metabolomics for laboratory diagnostics. J Pharm Biomed Anal. 2015;113:108\u201320.","journal-title":"J Pharm Biomed Anal"},{"key":"716_CR20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jprot.2018.09.020","volume":"193","author":"M Ca\u00f1adas-Garre","year":"2019","unstructured":"Ca\u00f1adas-Garre M, Anderson K, McGoldrick J, Maxwell AP, McKnight AJ. Proteomic and metabolomic approaches in the search for biomarkers in chronic kidney disease. J Proteomics. 2019;193:93\u2013122.","journal-title":"J Proteomics"},{"issue":"12","key":"716_CR21","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1007\/s13361-016-1469-y","volume":"27","author":"AC Schrimpe-Rutledge","year":"2016","unstructured":"Schrimpe-Rutledge AC, Codreanu SG, Sherrod SD, McLean JA. Untargeted metabolomics strategies-challenges and emerging directions. J Am Soc Mass Spectrom. 2016;27(12):1897\u2013905.","journal-title":"J Am Soc Mass Spectrom"},{"issue":"9","key":"716_CR22","first-page":"958","volume":"20","author":"M Naghashpour","year":"2017","unstructured":"Naghashpour M, Jafarirad S, Amani R, Sarkaki A, Saedisomeolia A. Update on riboflavin and multiple sclerosis: a systematic review. Iran J Basic Med Sci. 2017;20(9):958\u201366.","journal-title":"Iran J Basic Med Sci"},{"key":"716_CR23","volume-title":"Disorders of Purine Metabolism Dermatology","author":"O Braun-Falco","year":"2000","unstructured":"Braun-Falco O, Plewig G, Wolff HH, Burgdorf WH. Disorders of Purine Metabolism Dermatology. Berlin: Springer; 2000."},{"key":"716_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2021.12.016","author":"JP Dewulf","year":"2021","unstructured":"Dewulf JP, Marie S, Nassogne MC. Disorders of purine biosynthesis metabolism. Mol Genet Metab. 2021. https:\/\/doi.org\/10.1016\/j.ymgme.2021.12.016.","journal-title":"Mol Genet Metab"},{"key":"716_CR25","first-page":"1533","volume":"94","author":"RT Keenan","year":"2013","unstructured":"Keenan RT, Pillinger MH. Etiology and pathogenesis of hyperuricemia and gout. Rheumatology. 2013;94:1533\u201353.","journal-title":"Rheumatology"},{"key":"716_CR26","first-page":"36","volume-title":"Purine metabolism in the pathogenesis of hyperuricemia and inborn errors of purine metabolism associated with disease, Gout & Other Crystal Arthropathies","author":"RT Jim\u00e9nez","year":"2012","unstructured":"Jim\u00e9nez RT, Puig JG. Purine metabolism in the pathogenesis of hyperuricemia and inborn errors of purine metabolism associated with disease, Gout & Other Crystal Arthropathies. Amsterdam: Elsevier; 2012. p. 36\u201350."},{"issue":"5","key":"716_CR27","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jare.2017.04.008","volume":"8","author":"G Ragab","year":"2017","unstructured":"Ragab G, Elshahaly M, Bardin T. Gout: an old disease in new perspective\u2013a review. J Adv Res. 2017;8(5):495\u2013511.","journal-title":"J Adv Res"},{"key":"716_CR28","first-page":"449","volume-title":"Chapter 18 Purine and pyrimidine metabolism Medical Biochemistry 2nd","author":"A Blanco","year":"2022","unstructured":"Blanco A, Blanco G. Chapter 18 Purine and pyrimidine metabolism Medical Biochemistry 2nd. Cambridge Massachusetts: Academic Press; 2022. p. 449\u201360."},{"key":"716_CR29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198707093170209","author":"IH Fox","year":"1987","unstructured":"Fox IH, Palella TD, Kelley WN. Hyperuricemia: a marker for cell energy crisis. New England J Med. 1987. https:\/\/doi.org\/10.1056\/NEJM198707093170209.","journal-title":"New England J Med"},{"key":"716_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2018.101072","volume":"21","author":"HM Schmidt","year":"2019","unstructured":"Schmidt HM, Kelley EE, Straub AC. The impact of xanthine oxidase (XO) on hemolytic diseases. Redox Biol. 2019;21: 101072.","journal-title":"Redox Biol"},{"key":"716_CR31","first-page":"010846","volume":"12","author":"H Dickinson","year":"2014","unstructured":"Dickinson H, Bain E, Wilkinson D, Middleton P, Crowther CA, Walker DW. Creatine for women in pregnancy for neuroprotection of the fetus. Cochrane Database Syst Rev. 2014;12:010846.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"716_CR32","first-page":"679","volume":"56","author":"C Ben Salem","year":"2017","unstructured":"Ben Salem C, Slim R, Fathallah N, Hmouda HJR. Drug-induced hyperuricaemia and gout. Rheumatology. 2017;56(5):679\u201388.","journal-title":"Rheumatology"},{"issue":"17","key":"716_CR33","doi-asserted-by":"publisher","first-page":"9221","DOI":"10.3390\/ijms22179221","volume":"22","author":"H Yanai","year":"2021","unstructured":"Yanai H, Adachi H, Hakoshima M, Katsuyama H. Molecular biological and clinical understanding of the pathophysiology and treatments of hyperuricemia and its association with metabolic syndrome, cardiovascular diseases and chronic kidney disease. Int J Mol Sci. 2021;22(17):9221.","journal-title":"Int J Mol Sci."},{"issue":"6","key":"716_CR34","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1053\/j.ajkd.2017.12.009","volume":"71","author":"RJ Johnson","year":"2018","unstructured":"Johnson RJ, Bakris GL, Borghi C, Chonchol MB, Feldman D, Lanaspa MA, Merriman TR, Moe OW, Mount DB, Sanchez Lozada LG, Stahl E, Weiner DE, Chertow GM. Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop organized by the national kidney foundation. Am J Kidney Dis. 2018;71(6):851\u201365.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"716_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0192770","volume":"13","author":"A Etinger","year":"2018","unstructured":"Etinger A, Kumar SR, Ackley W, Soiefer L, Chun J, Singh P, Grossman E, Matalon A, Holzman RS, Meijers B, Lowenstein J. The effect of isohydric hemodialysis on the binding and removal of uremic retention solutes. PLoS ONE. 2018;13(2): e0192770.","journal-title":"PLoS ONE"},{"issue":"4","key":"716_CR36","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3390\/toxins12040229","volume":"12","author":"G Lano","year":"2020","unstructured":"Lano G, Burtey S, Sall\u00e9e M. Indoxyl sulfate, a uremic endotheliotoxin. Toxins. 2020;12(4):229.","journal-title":"Toxins"},{"issue":"6","key":"716_CR37","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3390\/toxins10060226","volume":"10","author":"RD Mair","year":"2018","unstructured":"Mair RD, Sirich TL, Meyer TW. Uremic toxin clearance and cardiovascular toxicities. Toxins. 2018;10(6):226.","journal-title":"Toxins"},{"issue":"8","key":"716_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135657","volume":"10","author":"H Tanaka","year":"2015","unstructured":"Tanaka H, Sirich TL, Plummer NS, Weaver DS, Meyer TW. An enlarged profile of uremic solutes. PLoS ONE. 2015;10(8): e0135657.","journal-title":"PLoS ONE"},{"issue":"1","key":"716_CR39","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/toxins10010033","volume":"10","author":"R Vanholder","year":"2018","unstructured":"Vanholder R, Pletinck A, Schepers E, Glorieux G. Biochemical and clinical impact of organic uremic retention solutes: a comprehensive update. Toxins. 2018;10(1):33.","journal-title":"Toxins"},{"key":"716_CR40","doi-asserted-by":"publisher","first-page":"6943860","DOI":"10.1155\/2020\/6943860","volume":"2020","author":"B Han","year":"2020","unstructured":"Han B, Gong M, Li Z, Qiu Y, Zou Z. NMR-based metabonomic study reveals intervention effects of polydatin on potassium oxonate-induced hyperuricemia in rats. Oxid Med Cell Longev. 2020;2020:6943860.","journal-title":"Oxid Med Cell Longev"},{"issue":"2","key":"716_CR41","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.apsb.2019.10.007","volume":"10","author":"L Pan","year":"2020","unstructured":"Pan L, Han P, Ma S, Peng R, Wang C, Kong W, Cong L, Fu J, Zhang Z, Yu H, Wang Y, Jiang J. Abnormal metabolism of gut microbiota reveals the possible molecular mechanism of nephropathy induced by hyperuricemia. Acta Pharm Sin B. 2020;10(2):249\u201361.","journal-title":"Acta Pharm Sin B"},{"issue":"12","key":"716_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190194","volume":"12","author":"Y Yun","year":"2017","unstructured":"Yun Y, Yin H, Gao Z, Li Y, Gao T, Duan J, Yang R, Dong X, Zhang L, Duan W. Intestinal tract is an important organ for lowering serum uric acid in rats. PLoS ONE. 2017;12(12): e0190194.","journal-title":"PLoS ONE"},{"key":"716_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.524236","volume":"11","author":"Q Lv","year":"2020","unstructured":"Lv Q, Xu D, Zhang X, Yang X, Zhao P, Cui X, Liu X, Yang W, Yang G, Xing S. Association of hyperuricemia with immune disorders and intestinal barrier dysfunction. Front Physiol. 2020;11: 524236.","journal-title":"Front Physiol"},{"issue":"5","key":"716_CR44","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1039\/D1FO03206B","volume":"13","author":"H Zhao","year":"2022","unstructured":"Zhao H, Lu Z, Lu Y. The potential of probiotics in the amelioration of hyperuricemia. Food Funct. 2022;13(5):2394\u2013414.","journal-title":"Food Funct"},{"key":"716_CR45","first-page":"1","volume":"5","author":"J Wang","year":"2021","unstructured":"Wang J, Chen Y, Zhong H, Chen F, Regenstein J, Hu X, Cai L, Feng F. The gut microbiota as a target to control hyperuricemia pathogenesis: potential mechanisms and therapeutic strategies. Crit Rev Food Sci Nutr. 2021;5:1\u201311.","journal-title":"Crit Rev Food Sci Nutr"},{"issue":"1","key":"716_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000476074","volume":"137","author":"JS Brito","year":"2017","unstructured":"Brito JS, Borges NA, Esgalhado M, Magliano DC, Soulage CO, Mafra D. Aryl hydrocarbon receptor activation in chronic kidney disease: role of uremic toxins. Nephron. 2017;137(1):1\u20137.","journal-title":"Nephron"},{"issue":"1","key":"716_CR47","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1042\/bj0980266","volume":"98","author":"LJ King","year":"1966","unstructured":"King LJ, Parke DV, Williams RT. The metabolism of [2-14C] indole in the rat. Biochem J. 1966;98(1):266\u201377.","journal-title":"Biochem J"},{"issue":"1","key":"716_CR48","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1159\/000189284","volume":"74","author":"T Niwa","year":"1996","unstructured":"Niwa T, Miyazaki T, Tsukushi S, Maeda K, Tsubakihara Y, Owada A, Shiigai T. Accumulation of indoxyl-beta-D-glucuronide in uremic serum: suppression of its production by oral sorbent and efficient removal by hemodialysis. Nephron. 1996;74(1):72\u20138.","journal-title":"Nephron"},{"issue":"9","key":"716_CR49","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.3390\/ijms20092280","volume":"20","author":"S Adesso","year":"2019","unstructured":"Adesso S, Ruocco M, Rapa SF, Piaz FD, Raffaele Di Iorio B, Popolo A, Autore G, Nishijima F, Pinto A, Marzocco S. Effect of indoxyl sulfate on the repair and intactness of intestinal epithelial cells: role of reactive oxygen species\u2019 release. Int J Mol Sci. 2019;20(9):2280.","journal-title":"Int J Mol. Sci."},{"issue":"16","key":"716_CR50","doi-asserted-by":"publisher","first-page":"7384","DOI":"10.7150\/thno.45455","volume":"10","author":"Y Huang","year":"2020","unstructured":"Huang Y, Zhou J, Wang S, Xiong J, Chen Y, Liu Y, Xiao T, Li Y, He T, Li Y, Bi X, Yang K, Han W, Qiao Y, Yu Y, Zhao J. Indoxyl sulfate induces intestinal barrier injury through IRF1-DRP1 axis-mediated mitophagy impairment. Theranostics. 2020;10(16):7384\u2013400.","journal-title":"Theranostics"},{"issue":"3","key":"716_CR51","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.3390\/ijms22031135","volume":"22","author":"SF Rapa","year":"2021","unstructured":"Rapa SF, Prisco F, Popolo A, Iovane V, Autore G, Di Iorio BR, Dal Piaz F, Paciello O, Nishijima F, Marzocco S. Pro-Inflammatory effects of indoxyl sulfate in mice: impairment of intestinal homeostasis and immune response. Int J Mol Sci. 2021;22(3):1135.","journal-title":"Int J Mol Sci"},{"key":"716_CR52","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1007\/s00394-020-02414-x","volume":"60","author":"Y Guo","year":"2021","unstructured":"Guo Y, Yu Y, Li H, Ding X, Li X, Jing X, Chen J, Liu G, Lin Y, Jiang C, Liu Z, He Y, Li C, Tian Z. Inulin supplementation ameliorates hyperuricemia and modulates gut microbiota in Uox-knockout mice. Eur J Nutr. 2021;60:2217\u201330.","journal-title":"Eur J Nutr"},{"issue":"9","key":"716_CR53","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1038\/s41418-018-0070-2","volume":"25","author":"Q Hou","year":"2018","unstructured":"Hou Q, Ye L, Liu H, Huang L, Yang Q, Turner JR, Yu Q. Lactobacillus accelerates ISCs regeneration to protect the integrity of intestinal mucosa through activation of STAT3 signaling pathway induced by LPLs secretion of IL-22. Cell Death Differ. 2018;25(9):1657\u201370.","journal-title":"Cell Death Differ"},{"issue":"4","key":"716_CR54","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-019-0258-z","volume":"17","author":"A Lavelle","year":"2020","unstructured":"Lavelle A, Sokol H. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020;17(4):223\u201337.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"716_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120610","volume":"602","author":"M Puccetti","year":"2021","unstructured":"Puccetti M, Pariano M, Borghi M, Barola C, Moretti S, Galarini R, Mosci P, Ricci M, Costantini C, Giovagnoli S. Enteric formulated indole-3-carboxaldehyde targets the aryl hydrocarbon receptor for protection in a murine model of metabolic syndrome. Int J Pharm. 2021;602: 120610.","journal-title":"Int J Pharm"},{"issue":"2","key":"716_CR56","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.immuni.2013.08.003","volume":"39","author":"T Zelante","year":"2013","unstructured":"Zelante T, Iannitti RG, Cunha C, De Luca A, Giovannini G, Pieraccini G, Zecchi R, D\u2019Angelo C, Massi-Benedetti C, Fallarino F, Carvalho A, Puccetti P, Romani L. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity. 2013;39(2):372\u201385.","journal-title":"Immunity"},{"key":"716_CR57","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.coi.2020.12.004","volume":"70","author":"T Zelante","year":"2021","unstructured":"Zelante T, Puccetti M, Giovagnoli S, Romani L. Regulation of host physiology and immunity by microbial indole-3-aldehyde. Curr Opin Immunol. 2021;70:27\u201332.","journal-title":"Curr Opin Immunol"}],"container-title":["Chinese Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-023-00716-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13020-023-00716-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-023-00716-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T05:09:18Z","timestamp":1676524158000},"score":1,"resource":{"primary":{"URL":"https:\/\/cmjournal.biomedcentral.com\/articles\/10.1186\/s13020-023-00716-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,16]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["716"],"URL":"https:\/\/doi.org\/10.1186\/s13020-023-00716-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1801647\/v1","asserted-by":"object"}]},"ISSN":["1749-8546"],"issn-type":[{"value":"1749-8546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,16]]},"assertion":[{"value":"28 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved by the Guide for the Care and Use of Laboratory Animals of Jiangxi University of Chinese Medicine (2017\u2013004).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}